Opko Health Inc. - OPK STOCK NEWS

ModeX Therapeutics Inc. has been awarded a contract from BARDA to advance a platform and specific candidates to address viral infectious diseases. The contract includes an initial $59 million for the development of a next-generation MSTAR multispecific antibody for COVID-19. Additional funding of up to $109 million may be available for other viral pathogens. This collaboration strengthens ModeX's research and development programs.

OPKO Health, Inc. reports business highlights and financial results for Q2 2023. Highlights include FDA approval of NGENLA for pediatric growth hormone deficiency and a $90 million milestone payment from Pfizer. NGENLA approved in 44 markets, sales underway in 18 countries. ModeX Therapeutics advancing antiviral and immune-oncology product pipeline. BioReference Health focused on cost reductions and profitability. Q2 revenues of $265.4 million, operating income of $7.0 million.

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. The company's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 3rd beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. A webcast of the call can also be accessed at OPKO’s Investor Relations page. A telephone replay and webcast replay will be available after the completion of the live conference call.

Pfizer and OPKO Health announce FDA approval for NGENLA, a once-weekly treatment for children with growth hormone deficiency. NGENLA is expected to be available for prescribing in the US in August 2023.

OPKO Health, Inc. reports Q1 2023 financial results and business highlights. Highlights include a collaboration agreement with Merck, sales of NGENLA® by Pfizer, and BioReference Health's new dual-stain triage test. Q1 revenue increased in Pharmaceuticals, while Diagnostics revenue decreased due to lower COVID-19 testing volume. Consolidated total revenues decreased compared to Q1 2022. Operating loss decreased, and net loss included non-cash income. Cash and cash equivalents were $110.8 million as of March 31, 2023.

OPKO Health, Inc. (NASDAQ: OPK) will announce its financial results for the first quarter of 2023 on May 3, 2023, after market close. The company plans to host a conference call and webcast to discuss the results and provide financial guidance at 4:30 p.m. Eastern time on the same day. Interested participants are encouraged to pre-register for the call to receive a unique PIN for immediate access. A replay of the call will be available until May 10, 2023. OPKO is focused on establishing leading positions in biopharmaceuticals and diagnostics through its proprietary technologies and expertise.

OPKO Health, Inc. (NASDAQ: OPK) has announced an R&D Day event scheduled for March 20, 2023, at 4:00 p.m. Eastern time. This two-hour virtual event will feature presentations from OPKO executives regarding ModeX Therapeutics' multispecific technology platforms, focusing on oncology and infectious diseases. Management will also discuss the MDX-2201 technology associated with a recently announced collaboration with Merck for a vaccine targeting Epstein-Barr virus. Attendees can access the live and archived webcast on OPKO’s Investor Relations website and participate in a Q&A session afterward.

OPKO Health announced an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201, a preclinical nanoparticle vaccine targeting the Epstein-Barr virus (EBV). This vaccine aims to address the health challenges posed by EBV, including infectious mononucleosis and associated cancers. Under the agreement, OPKO will receive an upfront payment of $50 million and potential milestone payments totaling up to $872.5 million, in addition to royalties on global sales. The collaboration highlights ModeX's innovative multi-targeting approach and Merck's expertise in vaccine development.

OPKO Health, Inc. (NASDAQ: OPK) reported its fourth-quarter financial results for 2022, noting total revenues of $185.4 million, down from $401.3 million in 2021. The operating loss improved to $55.3 million from $63.1 million year-over-year. Significant highlights included revenue growth in pharmaceuticals, with product sales rising to $37.9 million, primarily from NGENLA® and RAYALDEE. However, diagnostics revenue plummeted to $139.4 million due to decreased COVID-19 testing. The net loss was $85.2 million, or $0.11 per share, compared to a net loss of $73.8 million in the prior year. Cash and cash equivalents stood at $153.2 million.